Yorkshire AI platform aiming to transform drug development named finalist
gazetteherald.co.uk Sep 20, 2026

Yorkshire AI platform aiming to transform drug development named finalist

AI-summarised brief · reviewed before publication

ConsoneAI, a Wetherby‑based AI firm, has been named a finalist in the Royal Society of Chemistry’s 2026 Emerging Technologies Competition for its drug‑development platform, DioScor. The system predicts drug efficacy and side‑effects across genders, ethnicities, and age groups in 90 seconds, using AI to model human and animal responses while accounting for genetic and demographic variables. Founder Mo Kosar highlighted the platform’s potential to shorten drug approval timelines and reduce bias in clinical trials. DioScor also offers a method to map animal toxicity data to humans, potentially lowering animal testing.

💡 Why It Matters

  • · By enabling rapid, inclusive safety profiling, DioScor could accelerate the delivery of safer, more equitable medicines, addressing long‑standing gaps in drug research.